{"id":538412,"date":"2021-04-14T01:46:01","date_gmt":"2021-04-14T01:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538412"},"modified":"2021-04-14T01:46:01","modified_gmt":"2021-04-14T01:46:01","slug":"monoclonal-antibodies-market-has-been-estimated-to-account-for-1386-billion-in-revenues-by-2024-grand-view-research-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/monoclonal-antibodies-market-has-been-estimated-to-account-for-1386-billion-in-revenues-by-2024-grand-view-research-inc_538412.html","title":{"rendered":"Monoclonal Antibodies Market Has Been Estimated To Account For $138.6 Billion In Revenues By 2024 | Grand View Research, Inc."},"content":{"rendered":"
\"Monoclonal<\/a><\/p>\n
\n
“Grand View Research, Inc. \u2013 Market Research And Consulting.”<\/div>\n<\/div>\n<\/div>\n
According to a new report by Grand View Research, Inc., the Monoclonal Antibodies are approved by the FDA as part of the Coronavirus Treatment Acceleration Program. The monoclonal antibody treatments are being made available to certain patients suffering from Covid-19 infection, while research and studies on its safety and effectiveness continue.<\/div>\n

The global monoclonal antibodies (mAbs) market<\/a><\/strong> was valued at USD 85.4 billion<\/strong> in 2015<\/strong> and is expected to reach a value of USD 138.6 billion<\/strong> by 2024<\/strong>. The market’s growth is driven by factors such as the increasing R&D activities for the development of therapeutic mAbs.  Furthermore, supportive government initiatives are further driving the overall market growth. The production of therapeutic antibodies has gained a rampant demand and is a vital factor projected to fuel the market growth over the forecast period.<\/p>\n

Etesevimab and Bamlanivimab are monoclonal antibodies used specifically against the SARS-CoV-2 spike protein. Bamlanivimab and Etesevimab when administered in combination, can effectively treat patients with mild Covid-19. The National Institutes of Health (NIH) COVID-19 Treatment rules recommend that REGEN-COV™ usage and is approved by the FDA. Some of the other FDA-approved monoclonal antibodies include Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn), Dupixent® (dupilumab), REGEN-COVTM (casirivimab with imdevimab), Libtayo® (cemiplimab-rwlc), Kevzara® (sarilumab), Praluent® (alirocumab), Evkeeza™ (evinacumab-dgnb). <\/p>\n

Browse Full Report With Table Of Content @ <\/strong>https:\/\/www.grandviewresearch.com\/industry-analysis\/monoclonal-antibodies-market<\/a><\/p>\n

Monoclonal Antibodies Market Report Highlights<\/strong><\/p>\n

•<\/strong> In vivo technology<\/strong> is affordable than in vitro production techniques<\/strong>. The in vivo production technique is preferred for the high concentration of mAbs obtained through this method<\/p>\n

• <\/strong>Therapeutic mAbs<\/strong> has found a widespread application in cancer treatment and the increasing occurrence of cancer including including brain tumor, non-small cell lung, breast, colorectal, ovarian, gastric, Hodgkin’s lymphoma, and melanoma is contributing to the expantion of the mAbs vertical<\/p>\n

• <\/strong>North America<\/strong> dominated the market in 2015 due to the presence of a robust healthcare infrastructure, ample government funding, and technological advancements<\/p>\n

Ask for Sample Pages @ <\/strong>https:\/\/www.grandviewresearch.com\/industry-analysis\/monoclonal-antibodies-market\/request\/rs1<\/a><\/p>\n

Monoclonal Antibodies Market Segmentation<\/strong><\/p>\n

Grand View Research has segmented the monoclonal antibodies market by source type, production, indication, end-use, and region:<\/p>\n

Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 – 2024)<\/strong><\/p>\n

    •<\/strong> Murine
    •<\/strong> Chimeric
    •<\/strong> Humanized
    •<\/strong> Human<\/p>\n

Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 – 2024)<\/strong><\/p>\n

    •<\/strong> In Vivo
    •<\/strong> In Vitro<\/p>\n

Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 – 2024)<\/strong><\/p>\n

    •<\/strong> Cancer
    •<\/strong> Autoimmune Diseases
    •<\/strong> Inflammatory Diseases
    •<\/strong> Infectious Diseases
    •<\/strong> Microbial Diseases
    •<\/strong> Others<\/p>\n

Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 – 2024)<\/strong><\/p>\n

    •<\/strong> Hospitals
    •<\/strong> Research Institutes
    •<\/strong> Others<\/p>\n

Monoclonal Antibodies Regional Outlook (Market Revenue in USD Billion, 2013 – 2024)<\/strong><\/p>\n

    •<\/strong> North America
        • The U.S.
        • Canada
    •<\/strong> Europe
        • Germany
        • The U.K.
   • <\/strong>Asia Pacific
        • China
        • India
        • Japan
    •<\/strong> Latin America
        • Brazil
        • Mexico
    •<\/strong> Middle East & Africa
        • South Africa<\/p>\n

List of Key Players of Monoclonal Antibodies Market<\/strong><\/p>\n

    •<\/strong> Novartis AG, Pfizer, Inc.
    •<\/strong> GlaxoSmithKline plc
    •<\/strong> Amgen, Inc.
    •<\/strong> Merck & Co., Inc.
    •<\/strong> Daiichi Sankyo Company, Ltd.
    •<\/strong> Abbott
    • <\/strong>AstraZeneca
    •<\/strong> Eli Lilly<\/p>\n

Speak to Analyst @ <\/strong>https:\/\/www.grandviewresearch.com\/inquiry\/989\/ibb<\/a><\/p>\n

About Grand View Research<\/strong><\/p>\n

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Grand View Research, Inc.<\/a>
Contact Person:<\/strong> Sherry James, Corporate Sales Specialist – U.S.A.
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1888202951
Address:<\/strong>Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City:<\/strong> San Francisco
State:<\/strong> California
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.grandviewresearch.com\/industry-analysis\/monoclonal-antibodies-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Grand View Research, Inc. \u2013 Market Research And Consulting.” According to a new report by Grand View Research, Inc., the Monoclonal Antibodies are approved by the FDA as part of the Coronavirus Treatment Acceleration Program. The monoclonal antibody treatments are … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,416],"tags":[],"class_list":["post-538412","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538412"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}